Interferon-α and gemcitabine (2′,2′-difluorodeoxycytidine) in adult and pediatric renal tumors

International Journal of Oncology

Volumn 11, Issue 3, 1997, Pages 623-627

  Rohde, Detlef ^a   Goertz, Markus ^a   Hayn, Heike Karina ^a   Cremer, Ulrich ^a   Jakse, Gerhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

2 ,2 difluorodeoxycytidine; Biochemotherapy; Interferons; Nephroblastoma; Renal cell carcinoma

Indexed keywords

GEMCITABINE; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MOUSE; NEPHROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0030748058     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Atzpodien J, Kirchner H, Hänninen EL, Deckert M, Fenner M and Poliwoda H: Interlcukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 29A (Suppl. 5): 6-8, 1993.
2. Palmer NF and Sutow W: Clinical aspects of the rhabdoid tumor of the kidney: a report of the National Wilms' Tumor Study Group. Med Pediat Oncol 11: 242-245, 1983.
3. D'Angio GJ, Brewlow N, Beckwith JB, Evans A, Baum H, deLorimier A, Fernbach D, Hrabovsky E, Jones B and Kelalis P: Treatment of Wilms' tumor: results of the third National Wilms' Tumor Study. Cancer 64: 349-360, 1989.
4. Tournadc MF, Lemerle J, Habrand JL, Gauthier F and MacDowell H: Tumours of the kidney. In: Cancer in Children. Voute PA, Barrett A and Lemmerle J (eds). Springer, Berlin pp244-255, 1992.
5. Mentkevich GL, Durnow LA and Kiselev AV: Interferon-alpha in the treatment of pediatric malignancies. J Interferon Res 9: S208, 1989.
6. Heinemann V, Hertel LW, Grindey GB and Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031, 1988.
7. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmocol 38: 567-572, 1990.
8. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GM and Plunkett W: Cellular elimination of 2′,2′-difluorodeoxy-cytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52: 533-539, 1992.
9. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodcoxycytidine on DNA-synthesis. Cancer Res 51: 6110-6117, 1991.
10. DeMulder PHM, Weissbach L, Jakse G, Osieka R, Blatter J and Ermisch S: Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37:491-495, 1996.
11. Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A and Wong D: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4: 331-332, 1993.
12. Maniatis M (ed): Molecular cloning. A laboratory manual. Cold Spring Harbor, NY, USA, 1982.
13. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica P, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
14. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd M: New colorimetric assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
15. Naito S, von Eschenbach ACC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109-4115, 1986.
16. Boven E, Schipper H, Erkelens CA, Hatty SA and Pinedo HM: The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 68: 52-56, 1993.
17. Braakhuis BJ, von Dongen GA, Vermorken-JB and Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 51: 211-214, 1991.
18. Cory AH, Hertel LW, Kroin JS and Cory JG: Effects of 2′,2′-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells. Oncol Res 5: 59-63, 1993.
19. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor activity of gcmcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
20. Kristjanscn PE, Quistorff B, Spang-Thomscn M and Hansen HH: Intratumoral pharmacokinetic analysis by 19F-magnctic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. Ann Oncol 4: 157-160, 1993.
21. Ruiz van Haperen VW, Veerman G, Vermerken JB and Peters GJ: 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46: 1107-1112, 1990.
22. Lilenbaum RC and Green MR: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11: 1391-1402, 1993.
23. Moore DF, Pazdur R, Daugherty K, Rarassof P and Abbmzzese JI: Phase II study of gemcitaine in advanced colorectal adenocarcinoma. Invest New Drugs 10: 323-325, 1992.
24. Pitman K and Selby P: The management of renal cell carcinoma. Crit Rev Oncol Hematol 16: 181-200, 1993.
25. Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Amer 20: 283-295, 1993.
26. Elias L and Sandoval JM: Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163: 867-874, 1989.
27. Wadler S and Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473-3486, 1990.
28. Brown KW, Shaw AP, Poirier V, Tylor SJ, Berry PJ, Mott MG and Maitland NJ: Loss of chromosome 11p alleles in cultured cells derived from Wilms' tumours. Br J Cancer 60: 25-29, 1989.
29. Garvin AJ, Surrette F, Hintz DS, Rudisill MT, Sens MA and Sens DA: The in vitro growth and characterization of the skeletal muscle component of Wilms' tumor. Am J Pathol 121: 298-310, 1985.
30. Gansler T, Furlanetto R, Gramling TS, Robinson KA, Blocker N, Buse MG, Sens DA and Garvin AJ: Antibody to type I insulin-like growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol 135: 961-966, 1989.
31. Garvin AJ, Conleton L, Inabnett T, Gansler T and Sens DA: Growth characteristics of human Wilms' tumor in nude mice. Pediat Pathol 8: 599-615, 1988.
32. Hazen-Martin DJ, Garvin AJ, Gansler T, Tarnowski BI and Sens DA:. Morphology and growth characteristics of epithelial cells from classic Wilms' tumors. Am J Pathol 142: 893-905, 1993.
33. Gaynon PS, Nachman J and Wolff JA: Chemotherapy of Wilms' tumor. Pochedly C and Baum ES (eds). Elsevier, NY, USA, pp327-337, 1984.
34. Homma A and Aso Y: Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay. Eur Urol 25: 164-170, 1994.
35. Ishii Y and Tsukagoshi S: The synergistic effect of human recombinant interfcron-alpha 2a in combination with interferon-gamma and the induction of interferon-alpha 2a receptor by interferon-gamma. J Pharmacobiodyn 12: 299-304, 1989.
36. Matsuyama H, Yoshihiro S, Ohmoto Y, Yamamoto N and Naito K: Direct and indirect effects of human interferon alpha on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effect. Cancer Immunol Immunother 37: 84-88, 1993.
37. Ohmura K and Tsukamoto T: Antiproliferative effect of interferon-alpha on human renal cell carcinoma in clonogenic assay - single and combination effect with cancer chemotherapeutic agent. Hinyokika Kiyo 35: 737-747, 1989.
38. Tomita Y, Watanabe H, Kobayashi H, Nishiyama T, Tsuji S, Fujiwara M and Sato S: Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells. Cancer Immunol Immunother 35: 381-387, 1992.
39. Hasui M, Saikawa Y, Miura M, Takano N, Ueno Y, Yachie A, Miyawaki T and Taniguche N: Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combine immunodeficiency (seid) and athymic (nude) mice. Cell Immunol 120: 230-239, 1989.